Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!. Issue 1 (February 2020)

• Record Type: Journal Article
• Authors: Čolić, Jelena; Matucci Cerinic, Marco; Guiducci, Serena; Damjanov, Nemanja
• Is Part Of: Journal of scleroderma and related disorders. Volume 5:Issue 1(2020)
• Page Start: 6
• Page End: 20
• Publication Date: 2020-02
• Subjects: Systemic sclerosis -- microparticles -- biomarkers -- endothelial damage -- fibrosis; Scleroderma (Disease) -- Periodicals; Systemic scleroderma -- Periodicals; Fibrosis -- Periodicals; 616.544
• DOI: 10.1177/2397198319857356
• Languages: English
• ISSNs: 2397-1983

Abstract

Systemic sclerosis is the main systemic fibrotic disease with unknown etiology characterized by peripheral microvascular injury, activation of immune system, and wide-spread progressive fibrosis. Microparticles can be derived from any cell type during normal cellular differentiation, senescence, and apoptosis, and also upon cellular activation. Carrying along a broad range of surface cytoplasmic and nuclear molecules of originating cells, microparticles are closely implicated in inflammation, thrombosis, angiogenesis, and immunopathogenesis. Recently, microparticles have been proposed as biomarkers of endothelial injury, which is the primary event in the genesis of tissue fibrosis. Microparticles may have a role in fostering endothelial to mesenchymal transition, thus giving a significant contribution to the development of myofibroblasts, the most important final effectors responsible for tissue fibrosis and fibroproliferative vasculopathy. Thanks to potent profibrotic mediators, such as transforming growth factor beta, platelet-derived growth factor, high mobility group box 1 protein, nicotinamide adenine dinucleotide phosphate oxidase 4, and antifibrotic agents, such as matrix metalloproteinases, microparticles may play an opposite role in fibrosis.